ClinicalTrials.gg
Not yet recruitingNCT07602140Updated May 22, 2026

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

A Phase 2 interventional study of TACE combined with thermal ablation and Targeted Therapy in Gastric Cancer With Liver Metastases, sponsored by Shandong Provincial Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Shandong Provincial Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicenter, single-arm prospective clinical trial designed to evaluate the efficacy of TACE combined with thermal ablation, antibody-drug conjugates, immune checkpoint inhibitors, and first-line chemotherapy for the treatment of HER2 - highly expressing gastric cancer with liver metastases.

02

Conditions studied

  • Gastric Cancer With Liver Metastases
03

In context

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Shandong Provincial Hospital is the lead sponsor of 64 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants voluntarily joined this study, signed forms, demonstrated good compliance, and cooperated with follow-up.
  2. Male or female, aged 18 or older and 75 or younger;
  3. score is 0-1;
  4. Expected survival time ≥ 3 months;
  5. Imaging examinations suggest gastric cancer with liver ;
  6. Histopathologically confirmed gastric adenocarcinoma and liver metastatic adenocarcinoma;
  7. Enhanced CT scans were used to observe the staining of liver metastases; tumors with good blood supply were included in this study.
  8. Immunohistochemical results of gastric adenocarcinoma and/or liver metastatic adenocarcinoma confirmed high expression of (defined as: IHC 2+ or 3+);
  9. No prior history of antibody-drug conjugate ( ADC ) therapy ; Note: Patients who have more than 6 months after receiving (radiotherapy) chemotherapy + radical surgery, or who have relapsed more than 6 months after completing adjuvant (radiotherapy) chemotherapy or radical concurrent chemoradiotherapy;
  10. Within 28 days prior to the first administration of the study drug, the target lesion had not received local treatment (including transarterial chemoembolization/TACE, hepatic artery infusion chemotherapy/TAC, radiotherapy, radiation embolization or ablation, etc.);
  11. There must be at least one liver metastasis meeting the following criteria:

At least one patient is eligible for TACE and/or thermal ablation treatment; 12. In addition to the ablated lesion, there is at least one in the liver or outside the liver (according to 1.1 criteria, the long axis of the tumor lesion on CT scan is ≥10 mm, and the short axis of the lymph node lesion on CT scan is ≥10 mm) (for assessing the remote effect).

1.3 . Damage caused by other treatments received by the subject has recovered, including those received other cytotoxic drugs, radiotherapy or surgery for ≥4 weeks, and the wounds have completely healed ; 1.4 . Subjects should not have previously received , PD-L1, CTLA-4, or CAR-T immunotherapy ; 1.5 . Asymptomatic or control of brain metastases after radiotherapy ; 1.6 . Major organ functions are normal, and subjects must meet the following laboratory indicators:

1)In the absence of granulocyte colony-stimulating factor use in the past 14 days, the (ANC) is ≥1.5 x 10⁹ /L .

2)10⁹ /L without blood transfusion in the past 14 days ; 3) >9 g/dL in the absence of blood transfusion or erythropoietin use within the past 14 days ; 4)There is no active bleeding, such as hematemesis, melena, gingival bleeding, epistaxis, or hemorrhoidal bleeding, and the fecal occult blood test is ≤ +.

5)Total ≤1.5 × (ULN); 6) (AST) and alanine aminotransferase (ALT) ≤5.0×ULN , alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, and total serum bilirubin (TBIL) ≤1.5×ULN.

7)Serum creatinine ≤1.5×ULN or ( CrCl ) ≥50 mL/min calculated according to the Cockcroft-Gault formula; For women: CrCl = (140 - age × weight (kg) × 0.85 / 72 × serum creatinine (mg/dL)) For males: CrCl = (140 - age × weight (kg) × 1.00 / 72 × serum creatinine (mg/dL)) 8)Good coagulation function is defined as an (INR) or prothrombin time (PT) ≤ 1.5 times the ULN; and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; (For patients receiving anticoagulation therapy, such as those taking anticoagulants like aspirin , warfarin, or clopidogrel , the medication should generally be discontinued for at least 5-7 days, and the investigator should determine that both INR and APTT are within a safe and effective therapeutic range).

9)Normal thyroid function is defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH exceeds the normal range, subjects with normal total T3 (or FT3) and FT4 may also be enrolled.

10)Cardiac enzyme levels within the normal range (simply laboratory abnormalities that are not , as determined by the researchers, are also allowed to be enrolled); 11)Doppler ultrasound assessment showed a (LVEF) ≥ 50%.

1.7 . Patients with potential fertility need to use a medically approved method (such as an intrauterine device, birth control pill, or condom) during the study treatment period and for one month after the end of the study treatment period; and must have a negative serum or urine HCG test within 72 hours before study enrollment, and must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

Subjects meeting the following criteria were not eligible for inclusion in this study:

  1. diagnosed with other malignant tumors within 5 years prior to the first dose and who are not cured (excluding radically resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has been radically removed);
  2. Currently participating in interventional clinical research treatment, or having received other drugs or used investigational devices within 4 weeks prior to the first dose;
  3. Previous treatment with the following: antibody-drug conjugates, , anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co-inhibit T cell receptors (e.g. CTLA-4, OX-40, CD137);
  4. Within 28 days prior to the first administration of the study drug, the target lesion had received local treatment (including transarterial chemoembolization/TACE, hepatic artery infusion chemotherapy/TAC, radiotherapy, radioembolization or ablation, etc.);
  5. The patient had received systemic treatment with traditional Chinese medicine or immunomodulatory drugs with antitumor indications within 2 weeks prior to the first dose ;
  6. Subjects with any active disease or a history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or whose childhood asthma was completely remitted and requires no intervention in adulthood are eligible to be included; subjects with asthma requiring medical intervention with bronchodilators are not eligible to be included).
  7. Subjects are currently using , or systemic or absorbable topical , to achieve immunosuppression (dose >10 mg/ day prednisone or other equivalent corticosteroids), and have continued to use them within 2 weeks prior to enrollment; Note: Physiological doses of glucocorticoids (≤10 mg/day prednisone or equivalent drugs) are permitted.
  8. Known allogeneic organ transplantation (excluding corneal transplantation) or hematopoietic stem cell transplantation;
  9. known to the study drugs vedicetumab , sintilimab, and tegafur ;
  10. Active gastrointestinal bleeding or high risk of bleeding within 2 weeks prior to screening; or gastrointestinal perforation/fistula within 6 months prior to screening; intestinal obstruction, within 30 days after major surgery, uncontrolled hypertension, class III-IV heart failure, or severe hepatic or renal failure (class 4).
  11. Prior to starting treatment, the individual has not fully recovered from any toxicity and/or complications caused by any intervention (i.e., ≤ grade 1 or at baseline, excluding fatigue or hair loss).
  12. Known history of (HIV) infection (i.e., HIV 1/2 antibody positive );
  13. Untreated active (defined as HBsAg positive and HBV-DNA copy number greater than the value in the laboratory of the research center);

Note : Hepatitis B subjects who meet the following criteria may also be enrolled :

  1. before the first dose , the subject should receive anti-HBV therapy throughout the study chemotherapy treatment to avoid viral reactivation.
  2. Subjects with positive, negative, anti-HBs, or negative HBV viral loads do not require prophylactic anti-HBV treatment, but close monitoring for viral reactivation is necessary.

14.Subjects with active infection (HCV antibody positive and HCV-RNA level above the detection limit); 15.Those who have received a within 4 weeks prior to screening or plan to receive any vaccine during the study period (Note: Injectable inactivated virus vaccines against seasonal influenza are permitted within 30 days prior to the first dose; however, intranasal live attenuated influenza vaccines are not permitted).

16.Pregnant or breastfeeding women; 17.The presence of any serious or uncontrollable systemic disease, such as:

  1. Significant and uncontrollable abnormalities in rhythm, conduction, or morphology on resting , such as complete left bundle branch block, second-degree or higher cardiac conduction block, ventricular arrhythmia, or atrial fibrillation.
  2. According to NYHA standards, heart failure is classified as grade III or IV, or echocardiography shows a (LVEF) \<50%; unstable angina, congestive heart failure, or NYHA grade 3 or higher heart failure.
  3. Subjects who had experienced acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction or acute coronary syndrome within one month, and whose cardiovascular clinical symptoms or diseases were not well controlled;
  4. A history of non-infectious pneumonia requiring glucocorticoid therapy within one year prior to the first dose, or current clinically active interstitial lung disease;
  5. Active pulmonary tuberculosis;
  6. prior to the first use of the study drug , such as severe pneumonia, bacteremia, or infectious complications requiring hospitalization; baseline chest imaging showed active lung inflammation; symptoms and signs of infection existed within 2 weeks prior to the first use of the study drug; or oral and intravenous antibiotics were required, excluding prophylactic antibiotic use.
  7. The patient presents with clinically active diverticulitis, abdominal abscess, and gastrointestinal obstruction.
  8. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  9. Patients with a clear tendency to gastrointestinal bleeding include those with the following conditions: active local ulcer lesions and fecal occult blood (++) {those with ++ are not eligible}; those with a history of melena or hematemesis within the past 2 months;
  10. Those with abnormal coagulation function (>1.5 APTT>1.5 ULN) and bleeding tendency;
  11. Long-term unhealed wounds or fractures; major surgery or severe traumatic injury, fracture or ulcer within 4 weeks;
  12. Poorly controlled diabetes (fasting blood glucose (FBG) > 10 mmol/L);
  13. Urinalysis results indicate urine protein ≥++, and 24-hour urine protein quantification is confirmed to be >1.0 g;
  14. Patients with mental disorders who are unable to cooperate with treatment;
  15. Patients requiring treatment and with a history of lung disease that could potentially affect surgery include, but are not limited to, interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, and acute lung disease.
  16. The patient presents with clinically active diverticulitis, abdominal abscess, and gastrointestinal obstruction.
  17. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  18. Patients with mental disorders who are unable to cooperate with treatment;
  19. The presence of systemic diseases that researchers have determined are not stably controlled, including diabetes and hypertension; 18.Candidates must have a history of active autoimmune disease requiring systemic treatment (such as immunomodulatory drugs, corticosteroids, or immunosuppressants) within the past two years prior to screening, with permitted replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for renal or pituitary insufficiency), or a history of autoimmune disease. Candidates must have used systemic steroids (dose > 10 mg/day prednisone or equivalent dose of other glucocorticoids) or other systemic immunosuppressive therapies within 14 days prior to screening.

19.Patients must have had other malignant tumors within the 5 years prior to screening, except for those that have been cured by treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with radical surgery).

20.Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation; 21.Prior to starting treatment, the individual has not fully recovered from any toxicity and/or complications caused by any intervention (i.e., ≤ grade 1 or at baseline, excluding fatigue or hair loss).

22.Medical history or disease evidence that may interfere with trial results, prevent participants from participating in the study throughout the process, abnormal treatment or laboratory test values, or other circumstances that the investigator deems unsuitable for enrollment.

Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Interventional therapy + Chemotherapy + Targeted Therapy + Immunotherapy

    Other: TACE combined with thermal ablation · Drug: Targeted Therapy · Drug: Immunotherapy · Drug: Chemotherapy

Interventions

  • OtherTACE combined with thermal ablation

    The decision to perform transarterial chemoembolization (TACE) and/or thermal ablation is based on the blood supply, size, and number of liver metastases as determined by imaging examinations. Interventional therapy is repeated every two cycles, and TACE and/or thermal ablation therapy are selected based on the blood supply, location, size and number of liver metastases.

  • DrugTargeted Therapy

    Disitamab Vedotin For Injection: 2.5 mg/kg, day 1, IV drip , Q3W.

  • DrugImmunotherapy

    Sintilimab : 200mg , d1 , ivdrip , q3w

  • DrugChemotherapy

    S-1 : 40-60 mg/dose, orally, twice daily (bid), daily (days 1-14) , every 3 weeks (q3w).

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The proportion of subjects who achieve complete response (CR) and partial response (PR) among the total subjects.

    Time frame: Approximately 1 month after imaging examination

Secondary outcomes

  1. Progression-Free Survival(PFS)

    The time from treatment initiation to disease progression or death from any cause in cancer patients.

    Time frame: Approximately 1 day after disease progression or death from any cause in cancer patients.

  2. Disease Control Rate(DCR)

    The proportion of patients with tumor shrinkage or stabilization maintained for a certain duration, including those with complete response (CR), partial response (PR), and stable disease (SD).

    Time frame: Approximately 1 month after imaging examinatio

  3. Overall Survival (OS)

    The time from initial treatment to death from any cause

    Time frame: Approximately 2 years after last participant enrollment

  4. Adverse Event (AE)

    Type, incidence, grading (based on NCI-CTCAE v5.0 criteria), and duration of adverse event

    Time frame: Approximately 2 month after any treatment

  5. R0 resection rate

    Through postoperative pathological examination, it was confirmed that all surgical margins (including peripheral margins, deep margins, circumferential margins, etc.) of the excised specimen did not show any residual tumor cells under the microscope, indicating a negative margin and complete resection of the tumor without visible tumor remnants under the naked eye or microscope.

    Time frame: According to the postoperative pathological results, it is generally 2 weeks after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. PubMed 38051328 ↗
  • Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19. PubMed 34665942 ↗
  • Wang X, Fan B, Liu S. Comprehensive treatment focusing on transarterial chemoembolization for postoperative liver metastasis in gastric cancer patients. Am J Transl Res. 2024 Dec 15;16(12):7330-7342. doi: 10.62347/KWBT3893. eCollection 2024. PubMed 39822559 ↗
  • Vogl TJ, Gruber-Rouh T, Eichler K, Nour-Eldin NE, Trojan J, Zangos S, Naguib NN. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol. 2013 Feb;82(2):258-63. doi: 10.1016/j.ejrad.2012.10.006. Epub 2012 Nov 3. PubMed 23127803 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 24 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
May 22, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2029
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07602140
Lead sponsor
Shandong Provincial Hospital
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
May 22, 2026

Study contacts

Dan SHA
Contact
shadan@sdfmu.edu.cn
+86 13573175130

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion